BioXcel Therapeutics, Inc. Derivative, Gain (Loss) on Derivative, Net
BioXcel Therapeutics, Inc. (BTAI) reported Derivative, Gain (Loss) on Derivative, Net of $1.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:DerivativeGainLossOnDerivativeNet · last filed 2026-08-13
- BioXcel Therapeutics, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2026-06-30 was -$394.00K, a 159.43% decline year-over-year.
- BioXcel Therapeutics, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2026-03-31 was $1.52M, a 76.84% decline year-over-year.
- BioXcel Therapeutics, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2025-12-31 was $1.81M, a 44.96% decline year-over-year.
- BioXcel Therapeutics, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2025-09-30 was -$12.54M, a 360.29% decline year-over-year.
- BioXcel Therapeutics, Inc. derivative, gain (loss) on derivative, net for fiscal 2025 was -$3.50M, a 117.37% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. derivative, gain (loss) on derivative, net for fiscal 2024 was $20.18M, a 4507.31% increase from fiscal 2023.
- BioXcel Therapeutics, Inc. derivative, gain (loss) on derivative, net for fiscal 2023 was $438.00K.
- BioXcel Therapeutics, Inc. derivative, gain (loss) on derivative, net for fiscal 2022 was -$389.00K.
| Period end | Derivative, Gain (Loss) on Derivative, Net 3 month | Derivative, Gain (Loss) on Derivative, Net 6 month | Derivative, Gain (Loss) on Derivative, Net 9 month | Derivative, Gain (Loss) on Derivative, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$394.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.13M 10-Q · filed 2026-08-13 | $2.94M derived: sum of 3 quarters · filed 2026-08-13 | -$9.60M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.52M 10-Q · filed 2026-05-15 | $3.33M derived: sum of 2 quarters · filed 2026-05-15 | -$9.21M derived: sum of 3 quarters · filed 2026-05-15 | -$8.54M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$10.73M derived: sum of 2 quarters · filed 2026-03-27 | -$10.06M derived: sum of 3 quarters · filed 2026-08-13 | -$3.50M 10-K · filed 2026-03-27 |
| 2025-09-30 | -$12.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$11.88M derived: sum of 2 quarters · filed 2026-08-13 | -$5.32M 10-Q · filed 2025-11-12 | -$2.02M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $663.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $7.22M 10-Q · filed 2026-08-13 | $10.52M derived: sum of 3 quarters · filed 2026-08-13 | $15.34M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $6.56M 10-Q · filed 2026-05-15 | $9.86M derived: sum of 2 quarters · filed 2026-05-15 | $14.67M derived: sum of 3 quarters · filed 2026-05-15 | $26.71M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $8.11M derived: sum of 2 quarters · filed 2026-03-27 | $20.15M derived: sum of 3 quarters · filed 2026-03-27 | $20.18M 10-K · filed 2026-03-27 |
| 2024-09-30 | $4.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $16.85M derived: sum of 2 quarters · filed 2025-11-12 | $16.88M 10-Q · filed 2025-11-12 | $17.01M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $12.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $12.07M 10-Q · filed 2025-08-12 | $12.19M derived: sum of 3 quarters · filed 2025-08-12 | $12.19M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $30.00K 10-Q · filed 2025-05-12 | $152.00K derived: sum of 2 quarters · filed 2025-05-12 | $151.00K derived: sum of 3 quarters · filed 2025-05-12 | $699.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $121.00K derived: sum of 2 quarters · filed 2025-03-28 | $669.00K derived: sum of 3 quarters · filed 2025-03-28 | $438.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $547.00K derived: sum of 2 quarters · filed 2024-11-14 | $316.00K 10-Q · filed 2024-11-14 | -$136.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $548.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $317.00K 10-Q · filed 2024-08-06 | -$135.00K derived: sum of 3 quarters · filed 2024-08-06 | |
| 2023-03-31 | -$231.00K 10-Q · filed 2024-05-09 | -$683.00K derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$452.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | -$389.00K 10-K · filed 2024-03-22 | ||
| 2022-09-30 | $63.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |